CN1493593A - Polypeptide-human transcription regulate and control protein 44 and polynucleotide for coding said polypeptide - Google Patents

Polypeptide-human transcription regulate and control protein 44 and polynucleotide for coding said polypeptide Download PDF

Info

Publication number
CN1493593A
CN1493593A CNA021377308A CN02137730A CN1493593A CN 1493593 A CN1493593 A CN 1493593A CN A021377308 A CNA021377308 A CN A021377308A CN 02137730 A CN02137730 A CN 02137730A CN 1493593 A CN1493593 A CN 1493593A
Authority
CN
China
Prior art keywords
polynucleotide
polypeptide
sequence
human transcription
control albumen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA021377308A
Other languages
Chinese (zh)
Inventor
毛裕民
谢毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Biowindow Gene Development Inc
Original Assignee
Shanghai Biowindow Gene Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc
Priority to CNA021377308A priority Critical patent/CN1493593A/en
Publication of CN1493593A publication Critical patent/CN1493593A/en
Pending legal-status Critical Current

Links

Images

Abstract

A novel polypeptide-human transcription regulating protein 44, the polynucleotide for coding it, the process for preparing said polypeptide by DNA recombination, the application of said polypeptide in treating diseases, such as cancer, HIV infection, immunopathy, etc, the antagonist of said polypeptide and its medical action, and the application of said polynucleotide are disclosed.

Description

The polynucleotide of a kind of polypeptide-human transcriptional regulation protein 44 and this peptide species of coding
Technical field
The invention belongs to biological technical field, specifically, the invention describes a kind of polypeptide-human transcriptional regulation protein 44, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.
Background technology
The transcriptional control of eukaryotic gene is crucial for the normal expression of gene, finishes this process by transcriptional regulator usually, and they participate in determining gene at which kind of tissue and which kind of etap transcriptional start in vivo.Encode the gene of this proteinoid as undergoing mutation, and not only this gene self can not normal expression, and can not transcribe normally and express by many genes of its adjusting.Transcription factor to the regulation and control of genetic expression mainly by transcription factor combine with specific dna sequence dna, interaction between transcription factor and transcription factor and conventional interaction of transcribing mechanism finish.Difference according to structural motif, known DNA is conjugated protein can mainly to be divided into two classes: the albumen and zinc finger protein [Kamal Chowdhury, Heidi Rohdewohld et al., the Nucleic Acids Research that contain helix-turn-helix motif, 1988,16:9995-10011].
Zinc finger protein is the member in the nucleotide binding protein multigene family of coding zine ion mediation.People have separated from multiple organisms such as yeast, fruit bat, mouse and people and have obtained various zinc finger proteins.All zinc finger proteins all contain conservative finger tumor-necrosis factor glycoproteins (F/Y) XCXXCXXXFXXXXXLXXHXXXHTGEKP of 28-30 amino acid long, and some of them specified amino acid residues site is a high conservative.This sequence all contains a plurality of copies in a lot of different zinc finger proteins, its copy number difference then function is also different.Zinc finger protein depends on the quantity that refers to structure with the combining of DNA of different lengths, refer to that structure may be relevant with the combination stability of mixture, and mixture is the action site of rna polymerase transcribe more.Discover, it also is high conservative that the Zinc finger domain of many zinc finger proteins interconnects the zone, following sequence is contained in this zone usually: His-Thr-Gly-Gly-Lys-Pro-(Tyr, Phe)-X-Cys, wherein Histidine and halfcystine are the binding site of metal ion, and X is variable [Jeremy M.Berg, Annu.Rev.Biophys.Chem, 1990,19:405-421].
The member of zinc finger protein KRAB subfamily is all contained a KRAB (Kruppel-associated box) structural domain at the N-terminal of its aminoacid sequence.In the people's gene group, be determined and contained 300-700 zinc finger protein, wherein had 1/3rd gene to contain this structural domain in the gene that all Kruppel are relevant approximately, be the member in this subfamily.The KRAB structural domain is a zinc finger protein N-terminal DNA binding domains of being made up of 75 amino acid, high conservative [Judith F.Margolin et al., Proc.Natl.Acad.Sci.USA, 1994,91:4509-4513] on evolving.This structural domain is divided into two box structures of A, B, wherein is rich in the amino-acid residue of variation, forms two wetting ability spirals.Some contains KRAB A-box and KRAB B-box simultaneously member in the zinc finger protein KRAB subfamily, and some only contains KRAB A-box.Discover, the KRAB structural domain is that a potential is transcribed the inhibition structural domain, wherein the wetting ability spiral fragment of being made up of 45 amino acid suppresses necessary for transcribing, amino acid whose replacement will weaken the inhibit feature of albumen to transcribing in the spirane structure, thereby cause the imbalance of gene transcript expression and cause various growths and disease that pernicious disorder is relevant.The consequently activity of A box structure is weak relatively.[N.Tommerup?et?al.,Genomics,1995,27:259-264]。
People's of the present invention gene and human transcription regulate and control albumen 136 have 53% identity and 67% similarity on protein level.And both are similar, and the N-terminal of its aminoacid sequence contains the characteristic structural domain of zinc finger protein KRAB subfamily---KRAB structural domain A box structure; C-terminal then contains the characteristic structural domain of zinc finger protein family---C2H2 type Zinc finger domain.Based on above each point, so think the newcomer of new gene behaviour transcriptional regulation protein KRAB subfamily of the present invention, called after human transcription regulate and control albumen 44.And infer that with this its other members to human transcription regulate and control albumen 136 and human transcription regulate and control albumen KRAB subfamily are similar, have similar biological function.It reaches paracytic differentiation and breeds related [Vissing H., Meyer WKet al., 1995, FEBS Lett, 369:153-157] with normal in vivo.And its KRAB structural domain A box is a weak inhibition structural domain of transcribing, and can control proteic transcriptional expression amount effectively, and the sudden change of this structural motif may cause some proteic abnormality proliferations, thereby causes some relevant malignant diseases.
Because human transcription regulate and control albumen 44 albumen play an important role in regulating body critical functions such as cell fission and fetal development as mentioned above, and believe and relate to a large amount of albumen in these regulate processes, thereby need to identify human transcription regulate and control albumen 44 albumen of more these processes of participation in this area always, particularly identify this proteic aminoacid sequence.The separation of new person's transcriptional regulation protein 44 protein coding genes also provides the foundation for determining the effect of this albumen under healthy and morbid state.This albumen may constitute the basis of exploitation medical diagnosis on disease and/or curative, and it is very important therefore separating its coding DNA.
Summary of the invention
An object of the present invention is to provide isolating new polypeptide-human transcriptional regulation protein 44 with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of this polypeptide of coding.
Another object of the present invention provides the recombinant vectors of the polynucleotide that contain coding human transcription regulate and control albumen 44.
Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain coding human transcription regulate and control albumen 44.
Another object of the present invention provides the method for producing human transcription regulate and control albumen 44.
Another object of the present invention provides the antibody at polypeptide-human transcriptional regulation protein 44 of the present invention.
The present invention relates to a kind of isolated polypeptide, this polypeptide is the people source, and it comprises: have<polypeptide or its examples of conservative variations, bioactive fragment or the derivative of 210〉2 aminoacid sequences.Preferably, this polypeptide is to have<polypeptide of 210〉2 aminoacid sequences.
The invention still further relates to a kind of isolating polynucleotide, it comprises a kind of nucleotide sequence or its variant that is selected from down group:
(a) coding has<polynucleotide of the polypeptide of 210〉2 aminoacid sequences;
(b) with polynucleotide (a) complementary polynucleotide;
(c) with (a) or polynucleotide sequence (b) have the polynucleotide of at least 70% homogeny.
More preferably, the sequence of these polynucleotide is be selected from down group a kind of: (a) have<210〉1 in the sequence of 61-1272 position; (b) have<210〉1 in the sequence of 1-1796 position.
The present invention relates to a kind of carrier that contains polynucleotide of the present invention, particularly expression vector in addition; The host cell that this carrier of a kind of usefulness is genetically engineered comprises the host cell of conversion, transduction or transfection; A kind of method for preparing polypeptide of the present invention of cultivating described host cell and reclaiming expression product that comprises.
The invention still further relates to a kind of can with polypeptid specificity bonded antibody of the present invention.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
The invention provides a kind of polypeptide-human transcriptional regulation protein 44, it is basically by<210〉aminoacid sequence shown in 2 forms.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises fragment, derivative and the analogue of human transcription regulate and control albumen 44.As used herein, term " fragment ", " derivative " and " analogue " are meant biological function or the active polypeptide that keeps human transcription regulate and control albumen of the present invention 44 identical basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.
The invention provides isolating nucleic acid (polynucleotide), substantially by coding have<polynucleotide of the polypeptide of 210〉2 aminoacid sequences form.Polynucleotide sequence of the present invention comprises<210〉1 nucleotide sequence.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 1796 bases, its open reading frame (61-1272) 403 amino acid of having encoded.Find relatively that according to amino acid sequence homologous this polypeptide and human transcription regulate and control albumen 136 have 53% homology, deducibility goes out this human transcription regulate and control albumen 44 and has the similar 26S Proteasome Structure and Function of human transcription regulate and control albumen 136.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in<210〉1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has<210〉2 protein or polypeptide, but with the differentiated nucleotide sequence of coding region sequence shown in<210〉1.
The polynucleotide of the mature polypeptide of coding<210〉2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And, the polypeptide of interfertile polynucleotide encoding and<210〉and the mature polypeptide shown in 2 has identical biological function and activity.
The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding human transcription regulate and control albumen 44.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
The special polynucleotide sequence of coding human transcription regulate and control albumen 44 of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.
Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.
In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration human transcription regulate and control albumen 44; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect the protein product of human transcription regulate and control albumen 44 genetic expressions and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.
Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with the carrier of the present invention or transcriptional regulation protein 44 encoding sequences of directly choosing, and the method that produces polypeptide of the present invention through recombinant technology.
Among the present invention, the polynucleotide sequence of coding human transcription regulate and control albumen 44 can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.
Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains coding human transcription regulate and control albumen 44 and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, aLaboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The PL promotor of lambda particles phage; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.
Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.
Among the present invention, the polynucleotide of coding human transcription regulate and control albumen 44 or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.
Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results 2Method is handled, and used step is well-known in this area.Alternative is to use MgCl 2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.
By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce human transcription regulate and control albumen 44 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:
(1). with the polynucleotide (or varient) of everybody transcriptional regulation protein 44 of coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;
(2). in suitable medium, cultivate host cell;
(3). separation, protein purification from substratum or cell.
In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The antagonist of human transcription regulate and control albumen 44 comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of human transcription regulate and control albumen 44 can combine and eliminate its function with human transcription regulate and control albumen 44, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.
In screening during as the compound of antagonist, human transcription regulate and control albumen 44 can be added during bioanalysiss measure, determine to interactional influence between human transcription regulate and control albumen 44 and its acceptor whether compound is antagonist by measuring compound.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with human transcription regulate and control albumen 44 bonded peptide molecules obtains.During screening, generally tackle human transcription regulate and control albumen 44 molecules and carry out mark.
The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at human transcription regulate and control albumen 44 antigenic determinants.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The method of the available human transcription regulate and control albumen 44 direct injection immune animals of the production of polyclonal antibody (as rabbit, mouse, rat etc.) obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of preparation human transcription regulate and control albumen 44 include but not limited to hybridoma technology (Kohlerand Milstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-human transcription regulate and control albumen 44.
The antibody of anti-human transcription regulate and control albumen 44 can be used in the immunohistochemistry technology, detects the human transcription regulate and control albumen 44 in the biopsy specimen.
With the also available labelled with radioisotope of human transcription regulate and control albumen 44 bonded monoclonal antibodies, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of human transcription regulate and control albumen 44 high-affinities can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing human transcription regulate and control albumen 44 positive cells.
The disease that antibody among the present invention can be used for treating or prevention and human transcription regulate and control albumen 44 are relevant.The antibody that gives suitable dosage can stimulate or block the generation or the activity of human transcription regulate and control albumen 44.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization human transcription regulate and control albumen 44 levels.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.Human transcription regulate and control albumen 44 levels that detected in the test can and be used to the disease of diagnosing human transcription regulate and control albumen 44 to work with the importance of the human transcription regulate and control protein that lays down a definition white 44 in various diseases.
Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.
The polynucleotide of coding human transcription regulate and control albumen 44 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of human transcription regulate and control albumen 44 or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the human transcription regulate and control albumen 44 of expressing variation, to suppress endogenic human transcription regulate and control albumen 44 activity.For example, a kind of human transcription regulate and control albumen 44 of variation can be the human transcription regulate and control albumen 44 that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of 44 expression of human transcription regulate and control albumen or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding human transcription regulate and control albumen 44 are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding human transcription regulate and control albumen 44 is found in existing document (Sambrook, et al.).The polynucleotide of reorganization coding human transcription regulate and control albumen 44 can be packaged in the liposome and be transferred in the cell in addition.
Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
Suppress the oligonucleotide (comprising sense-rna and DNA) of human transcription regulate and control albumen 44mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
The polynucleotide of coding human transcription regulate and control albumen 44 can be used for the diagnosis with the relative disease of human transcription regulate and control albumen 44.The unconventionality expression of the expression that the polynucleotide of coding human transcription regulate and control albumen 44 can be used for detecting human transcription regulate and control albumen 44 people's transcriptional regulation protein 44 whether or under morbid state.As the dna sequence dna of the human transcription regulate and control albumen 44 of encoding can be used for biopsy specimen is hybridized to judge the expression situation of human transcription regulate and control albumen 44.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Personnel selection transcriptional regulation protein 44 special primers carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect human transcription regulate and control albumen 44.
The sudden change that detects human transcription regulate and control albumen 44 genes also can be used for diagnosing the relevant disease of human transcription regulate and control albumen 44.The form of human transcription regulate and control albumen 44 sudden change comprises that the point mutation compared with normal wild type human transcription regulate and control albumen 44 dna sequence dnas, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch MedicalLibrary).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.
Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Description of drawings
Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.
Fig. 1 is the amino acid sequence homology comparison diagram of inventor's transcriptional regulation protein 44 and human transcription regulate and control albumen 136.The top sequence is a human transcription regulate and control albumen 44, and the below sequence is a human transcription regulate and control albumen 136.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".
Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating human transcription regulate and control albumen 44.44kDa is proteinic molecular weight.The arrow indication is isolated protein band.
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1: the clone of human transcription regulate and control albumen 44
Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dye terminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 0426G01 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 0426G01 clone is 2381bp (as<210〉1 shown in), from 32bp to 592bp the open reading frame (ORF) of a 561bp arranged, the new protein of encoding (as<210〉2 shown in).We are with this clone's called after pBS-0426G01, encoded protein matter called after human transcription regulate and control albumen 44.
Embodiment 2:cDNA clone's homology retrieval
With the sequence and the encoded protein sequence thereof of human transcription regulate and control albumen 44 of the present invention, with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with human transcription regulate and control albumen 44 homologys of the present invention is a kind of known human transcription regulate and control albumen 136, and its encoded protein number is U09367 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 53%; Similarity is 67%.
Embodiment 3: with the gene of RT-PCR method clones coding human transcription regulate and control albumen 44
Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1:5’-ACGGCTGCGAGAAGACGAAGCTTAG-3’(<210>10)
Primer2:5’-AATTAATAACAATTCTTTATTAGC-3’(<210>11)
Primer1 for to be positioned at<the forward sequence that begins of 1bp of 210〉15 ' end;
Primer2 be<210〉1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/LTris-Cl, (pH8.5), 1.5mmol/L MgCl 2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows the dna sequence dna and<210 of PCR product〉1-1796bp shown in 1 is identical.
Embodiment 4:Northern blotting analyst transcriptional regulation protein 44 expression of gene:
Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- 32P dATP prepares by random priming 32The dna probe of P-mark.Used dna probe is human transcription regulate and control albumen 44 coding region sequences (61bp to 1272bp) of pcr amplification shown in Figure 1.Probe (about 2 * 10 with the 32P-mark 6Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH 2PO 4(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.
Embodiment 5: the vivoexpression of recombinant human transcriptional regulation protein 44, separation and purifying
According to<210〉1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:
Primer3:5’-CATGCTAGCATGCAAGAAATCTTCAGGAACCTGG-3’(<210>12)
Primer4:5’-CCCGAATTCCTAATCTTCCTTACATGTGTTGGGT-3’(<210>13)
5 ' end of these two sections primers contains NheI and EcoRI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, NheI and EcoRI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-0426G01 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-0426G01 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with NheI and EcoRI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-0426G01) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-0426G01) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein human transcription regulate and control albumen 44 of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 44kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end are identical with 15 amino-acid residues of N-end shown in<210〉2 as a result.
Embodiment 6 anti-human transcription regulate and control albumen 44 production of antibodies
Synthesize following human transcription regulate and control albumen 44 specific polypeptide with Peptide synthesizer (PE company product): NH2-Met-Gln-Glu-Ile-Phe-Arg-Asn-Leu-Ala-Ser-Val-Gly-Asn-Lys-Ser-COOH.
Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with human transcription regulate and control albumen 44 specifically.
Sequence table
<110〉Bode Gene Development Co., Ltd., Shanghai
The polynucleotide of<a 120〉peptide species--human transcription regulate and control albumen 44 and this peptide species of coding
<130>0426g01
<160>13
<170>PatentIn?version?3.1
<210>1
<211>660
<212>DNA
<213>Homo?sapiens
<220>
<221>CDS
<222>(32)..(592)
<223>
<400>1
acggctgcga?gaagacgaag?cttagggacg?g?ctg?cga?gaa?gac?gaa?gct?tag 52
Leu?Arg?Glu?Asp?Glu?Ala
1 5
ggg?atg?tga?tgc?aag?aaa?tct?tca?gga?acc?tgg?ctt?ctg?tag?gaa?aca 100
Gly?Met Cys?Lys?Lys?Ser?Ser?Gly?Thr?Trp?Leu?Leu Glu?Thr
10 15 20
aat?cag?aag?acc?aga?ata?tcc?aag?atg?act?tca?aaa?atc?ctg?gga?gaa 148
Asn?Gln?Lys?Thr?Arg?Ile?Ser?Lys?Met?Thr?Ser?Lys?Ile?Leu?Gly?Glu
25 30 35
atc?taa?gca?gtc?atg?tgg?tag?aga?gac?tgt?ttg?aaa?tta?aag?aag?gca 196
Ile Ala?Val?Met?Trp Arg?Asp?Cys?Leu?Lys?Leu?Lys?Lys?Ala
40 45 50
gtc?aat?atg?gag?aaa?cct?tca?gcc?agg?att?caa?att?tga?atc?tga?ata 244
Val?Asn?Met?Glu?Lys?Pro?Ser?Ala?Arg?Ile?Gln?Ile Ile Ile
55 60
aga?aag?ttt?cta?ctg?gag?taa?agc?cat?gtg?aat?gca?gtg?tgt?gtg?gaa 292
Arg?Lys?Phe?Leu?Leu?Glu Ser?His?Val?Asn?Ala?Val?Cys?Val?Glu
65 70 75
aag?tct?tca?tat?gtc?att?cag?ccc?ttc?ata?ggc?aca?tcc?tgt?ctc?aca 340
Lys?Ser?Ser?Tyr?Val?Ile?Gln?Pro?Phe?Ile?Gly?Thr?Ser?Cys?Leu?Thr
80 85 90 95
ttg?gaa?aca?aac?tat?ttg?agt?gtg?agg?aat?gtc?cag?aga?agt?tat?atc 388
Leu?Glu?Thr?Asn?Tyr?Leu?Ser?Val?Arg?Asn?Val?Gln?Arg?Ser?Tyr?Ile
100 105 110
att?gca?aac?aat?gtg?gga?aag?cct?tta?tct?ctc?tca?cca?gtg?ttg?aca 436
Ile?Ala?Asn?Asn?Val?Gly?Lys?Pro?Leu?Ser?Leu?Ser?Pro?Val?Leu?Thr
115 120 125
gac?aca?tgg?taa?cac?aca?cta?gta?atg?ggc?ctt?ata?agg?gtc?cag?tgt 484
Asp?Thr?Trp His?Thr?Leu?Val?Met?Gly?Leu?Ile?Arg?Val?Gln?Cys
130 135 140
atg?aga?agc?ctt?ttg?att?ttc?cta?gtg?tat?ttc?aaa?tgc?ctc?aga?gca 532
Met?Arg?Ser?Leu?Leu?Ile?Phe?Leu?Val?Tyr?Phe?Lys?Cys?Leu?Arg?Ala
145 150 155
ctt?aca?ctg?gag?aga?aaa?cat?ata?aat?gta?aac?att?gtg?ata?aag?cct 580
Leu?Thr?Leu?Glu?Arg?Lys?His?Ile?Asn?Val?Asn?Ile?Val?Ile?Lys?Pro
160 165 170
tca?att?att?caa?gttatcttcg?tgaacatgaa?agaactcata?ctggagagaa 632
Ser?Ile?Ile?Gln
175
accctatgca tgtaagaaat gtggtaaa
660
<210>2
<211>6
<212>PRT
<213>Homo?sapiens
<400>2
Leu?Arg?Glu?Asp?Glu?Ala
1 5
<210>3
<211>10
<212>PRT
<213>Homo?sapiens
<400>3
Cys?Lys?Lys?Ser?Ser?Gly?Thr?Trp?Leu?Leu
1 5 10
<210>4
<211>19
<212>PRT
<213>Homo?sapiens
<400>4
Glu?Thr?Asn?Gln?Lys?Thr?Arg?Ile?Ser?Lys?Met?Thr?Ser?Lys?Ile?Leu
1 5 10 15
Gly?Glu?Ile
<210>5
<211>4
<212>PRT
<213>Homo?sapiens
<400>5
Ala?Val?Met?Trp
1
<210>6
<211>21
<212>PRT
<213>Homo?sapiens
<400>6
Arg?Asp?Cys?Leu?Lys?Leu?Lys?Lys?Ala?Val?Asn?Met?Glu?Lys?Pro?Ser
l 5 10 15
Ala?Arg?Ile?Gln?Ile
20
<210>7
<211>7
<212>PRT
<213>Homo?sapiens
<400>7
Ile?Arg?Lys?Phe?Leu?Leu?Glu
1 5
<210>8
<211>60
<212>PRT
<213>Homo?sapiens
<400>8
Ser?His?Val?Asn?Ala?Val?Cys?Val?Glu?Lys?Ser?Ser?Tyr?Val?Ile?Gln
1 5 10 15
Pro?Phe?Ile?Gly?Thr?Ser?Cys?Leu?Thr?Leu?Glu?Thr?Asn?Tyr?Leu?Ser
20 25 30
Val?Arg?Asn?Val?Gln?Arg?Ser?Tyr?Ile?Ile?Ala?Asn?Asn?Val?Gly?Lys
35 40 45
Pro?Leu?Ser?Leu?Ser?Pro?Val?Leu?Thr?Asp?Thr?Trp
50 55 60
<210>9
<211>48
<212>PRT
<213>Homo?sapiens
<400>9
His?Thr?Leu?Val?Met?Gly?Leu?Ile?Arg?Val?Gln?Cys?Met?Arg?Ser?Leu
1 5 10 15
Leu?Ile?Phe?Leu?Val?Tyr?Phe?Lys?Cys?Leu?Arg?Ala?Leu?Thr?Leu?Glu
20 25 30
Arg?Lys?His?Ile?Asn?Val?Asn?Ile?Val?Ile?Lys?Pro?Ser?Ile?Ile?Gln
35 40 45
<210>10
<211>25
<212>DNA
<213>Homo?sapiens
<400>10
acggctgcga gaagacgaag cttag
25
<210>11
<211>24
<212>DNA
<213>Homo?sapiens
<400>11
aattaataac aattctttat tagc
24
<210>12
<211>34
<212>DNA
<213>Homo?sapiens
<400>12
catgctagca tgcaagaaat cttcaggaac ctgg
34
<210>13
<211>34
<212>DNA
<213>Homo?sapiens
<400>13
cccgaattcc taatcttcct tacatgtgtt gggt
34

Claims (10)

1, a kind of isolated polypeptide-human transcription regulate and control albumen 44 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in<210〉2 or the active fragments of its polypeptide, analogue or derivative.
2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in<210〉2.
3, polypeptide as claimed in claim 2 is characterized in that it comprises and has<polypeptide of the aminoacid sequence shown in 210〉2.
4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:
(a) coding have<210〉2 shown in the polynucleotide of the polypeptide of aminoacid sequence or its fragment, analogue, derivative;
(b) with polynucleotide (a) complementary polynucleotide; Or
(c) with (a) or the polynucleotide of at least 70% homogeny (b) are arranged.
5, polynucleotide as claimed in claim 4, it is characterized in that described polynucleotide comprise coding and have<210〉2 shown in the polynucleotide of aminoacid sequence.
6, polynucleotide as claimed in claim 4, it is characterized in that the sequence of described polynucleotide includes<210〉1 in the 61-1272 position sequence or<210〉1 in the sequence of 1-1796 position.
7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.
8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:
(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or
(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.
9, a kind of preparation method with human transcription regulate and control albumen 44 active polypeptide is characterized in that described method comprises:
(a) under expressing human transcriptional regulation protein 44 conditions, cultivate the described through engineering approaches host cell of claim 8;
(b) from culture, isolate and have human transcription regulate and control albumen 44 active polypeptide.
10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with human transcription regulate and control albumen 44 specificity bonded antibody.
CNA021377308A 2002-10-30 2002-10-30 Polypeptide-human transcription regulate and control protein 44 and polynucleotide for coding said polypeptide Pending CN1493593A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA021377308A CN1493593A (en) 2002-10-30 2002-10-30 Polypeptide-human transcription regulate and control protein 44 and polynucleotide for coding said polypeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA021377308A CN1493593A (en) 2002-10-30 2002-10-30 Polypeptide-human transcription regulate and control protein 44 and polynucleotide for coding said polypeptide

Publications (1)

Publication Number Publication Date
CN1493593A true CN1493593A (en) 2004-05-05

Family

ID=34231680

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA021377308A Pending CN1493593A (en) 2002-10-30 2002-10-30 Polypeptide-human transcription regulate and control protein 44 and polynucleotide for coding said polypeptide

Country Status (1)

Country Link
CN (1) CN1493593A (en)

Similar Documents

Publication Publication Date Title
CN1297999A (en) Human glutaminyl s-RNA synthatase 58 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1386856A (en) Polypeptide-aconitase-8.8 and polynucleotide for coding it
CN1493593A (en) Polypeptide-human transcription regulate and control protein 44 and polynucleotide for coding said polypeptide
CN1296975A (en) Polypeptide-human ribosomal protein L23 and polynucleotide for coding said polypeptide
CN1324831A (en) New polypeptide human non-insulin dependent diabetes related protein 25 and polynucleotides for encoding same
CN1493586A (en) Polypeptide-human transcription regulate and control protein 38 and polynucleotide for coding said polypeptide
CN1493588A (en) Polyepeptide-human transcription regulate and control protein 35 and polynucleotide for coding said polypeptide
CN1493596A (en) Polypeptide-human programming cell death protein 22 and polynucleotide for coding said polypeptide
CN1493585A (en) Polypeptide-human tubulin monomer releasing factor 28 and polynucleotide for coding said polypeptide
CN1324934A (en) New polypeptide glyceraldehyde-3-phosphate dehydrogenase 10 and polynucleotides for encoding same
CN1297052A (en) Polypeptide-human RNA unwinding enzyme 43 and polynucleotide for coding said polypeptide
CN1342686A (en) Polypeptide-human kidney-specific protein 35.53 and polynucleotide for cocing it
CN1493591A (en) Polypeptide-human protein synthetic protein L14, 22 and nucleotide for coding said polypeptide
CN1510044A (en) Polypeptide-human beta-transductor 41 and polynucleotide for encoding said polypeptide
CN1519250A (en) Polypeptide-human ring finger protein 27.17 and polynucleotide for encoding polypeptide
CN1493584A (en) New polypeptide-human tumour inhibiting factor 46 and polynucleotide for coding said polypeptide
CN1493595A (en) Polypeptide-human tumour protein 20 and polynucleotide for coding said polypeptide
CN1510134A (en) Polypeptide human protein tyrosine kinase 50 and polynucleotide for encoding it
CN1493590A (en) Polypeptide-human cell disintegrate regulatory protein 27 and polynucleotide for coding said polypeptide
CN1493690A (en) Polypeptide-human protein metabolic enzyme 29 and polynucleotide for coding said polypeptide
CN1493589A (en) Polypeptide-human cell regulate and control protein 54 and polynucleotide for coding said polypeptide
CN1493592A (en) Polypeptide-respiratory protein 18 and polynucleotide for coding said polypeptide
CN1406984A (en) Polypeptide-human zinc finger protein-66.77 and polynucleotide for encoding it
CN1485336A (en) Polypeptide- human clathrin 82 and polynucleotide for coding such polypeptide
CN1493583A (en) New polypeptide-hyman glucoprotein 42 and polynucleotide for coding said polypeptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication